Impact of variant histology on upstaging and survival in patients with nonmuscle invasive bladder cancer undergoing radical cystectomy
CONCLUSION: Patients with VH NMIBC undergoing RC are at significantly higher risk of upstaging at RC when compared to patients with pure urothelial NMIBC and have worse overall survival. While this study supports the concept of an aggressive treatment approach for patients with VH NMIBC, improvements in understanding of the disease are necessary to improve outcomes.PMID:38267301 | DOI:10.1016/j.urolonc.2023.12.008 (Source: Urologic Oncology)
Source: Urologic Oncology - January 24, 2024 Category: Urology & Nephrology Authors: J McFadden I Tachibana N Adra K Collins C Cary M Koch H Kaimakliotis T A Masterson K R Rice Source Type: research
Referral patterns and genetic testing outcomes in a contemporary hereditary renal cancer clinic
CONCLUSIONS: These findings are useful for referring physicians and patients in determining patient referral to hereditary cancer clinics, and for counseling patients undergoing genetic testing. Data from non-Caucasian patients and evolving implications of variants of unclear significance (VUS) may represent future research directions for hereditary renal cancer clinics.PMID:38267302 | DOI:10.1016/j.urolonc.2023.12.010 (Source: Urologic Oncology)
Source: Urologic Oncology - January 24, 2024 Category: Urology & Nephrology Authors: J McFadden J Hardesty C Schroeder G H Vance R S Boris Source Type: research
The association between frailty, hypogonadism, and postoperative outcomes among men undergoing radical cystectomy
CONCLUSIONS: These findings suggest that hypogonadism and preoperative frailty may be important to evaluate prior to undergoing RC.PMID:38262867 | DOI:10.1016/j.urolonc.2024.01.012 (Source: Urologic Oncology)
Source: Urologic Oncology - January 23, 2024 Category: Urology & Nephrology Authors: Daniel R Greenberg Stephen Rhodes Hriday P Bhambhvani Luis C Gago Edward M Schaeffer Joshua J Meeks Robert E Brannigan Jonathan E Shoag Joshua A Halpern Source Type: research
The association of body mass index with tumor aggression among men undergoing radical prostatectomy
CONCLUSIONS: Increased BMI is associated with adverse pathology in PZ tumors. TZ adverse pathology risk may be increased among obese men with GG1 or GG2 disease, which has implications for future studies assessing behavioral change among men whose tumors are actively monitored.PMID:38262868 | DOI:10.1016/j.urolonc.2023.12.013 (Source: Urologic Oncology)
Source: Urologic Oncology - January 23, 2024 Category: Urology & Nephrology Authors: Justin R Gregg Resa Magill Andrew M Fang Brian F Chapin John W Davis Mehrad Adibi Lisly Ch éry John Papadopoulos Curtis Pettaway Louis Pisters John F Ward Andrew W Hahn Carrie R Daniel Jerusha Bhaskaran Keyi Zhu Mireya Guerrero Miao Zhang Patricia Tronco Source Type: research
Clinical parameters for the prediction of occult lymph node metastasis in patients with negative PSMA-PET
CONCLUSION: The currently used nomogram is suboptimal in detecting patients with occult LNM. While the cut-off value to perform ePLND can be increased slightly following a negative PSMA-PET scan, more accurate methods of identifying these patients are needed. Whether ePLND can have a therapeutic benefit, as opposed to a diagnostic only, needs to be re-evaluated in the PSMA-PET era.PMID:38246806 | DOI:10.1016/j.urolonc.2023.12.016 (Source: Urologic Oncology)
Source: Urologic Oncology - January 21, 2024 Category: Urology & Nephrology Authors: Nicolai A Huebner Gabriel Wasinger Pawel Rajwa Irene Resch Stephan Korn Sazan Rasul Pascal Baltzer Larissa Pr üger Andreas Rauschmeier Christian Seitz Eva Comperat Shahrokh F Shariat Bernhard Grubm üller Source Type: research
Maximizing efficiency and ensuring safety: Exploring the outcomes of 2 consecutive open radical cystectomies by the same team within a single surgical day
CONCLUSION: Performing 2 consecutive open RCs within 1 day by the same surgical team is a safe approach in experienced hands. This strategy optimizes the utilization of surgical resources and addresses the growing demand for urologic care while maintaining high-quality patient care. Preoperative planning should consider patient-specific factors to minimize risks associated with major complications.MICRO ABSTRACT: This study evaluates the outcomes of performing 2 consecutive open radical cystectomies (RC) in a single day by the same surgical team. Data from 657 patients who underwent RC at a single tertiary medical center p...
Source: Urologic Oncology - January 21, 2024 Category: Urology & Nephrology Authors: Luisa Egen Frederik Wessels Allison Quan Niklas Westhoff Maximilian Christian Kriegmair Patrick Honeck Maurice Stephan Michel Karl-Friedrich Kowalewski Source Type: research
Magnetic resonance imaging-ultrasound fusion guided focal cryoablation for men with intermediate-risk prostate cancer
CONCLUSION: MRI-US-guided cryoablation to target lesions in intermediate-risk CaP appears to be a safe treatment option, with functional outcomes indicating minimal short and intermediate-term morbidity and acceptable oncological outcomes. However, despite close monitoring and follow-up, there is still a limitation in accurately predicting/detecting pathological failure after FT. The long-term durability of FT for intermediate-risk, organ-confined CaP remains uncertain.PMID:38245407 | DOI:10.1016/j.urolonc.2024.01.003 (Source: Urologic Oncology)
Source: Urologic Oncology - January 20, 2024 Category: Urology & Nephrology Authors: Abhinav Sidana Shima Tayebi Fernando Blank Daniel J Lama Meredith Meyer Yusef Saeed Juliana Tobler Wei-Wen Hsu Sadhna Verma Source Type: research
Surgeon seniority and experience have no effect on CaP detection rates using MRI/TRUS fusion-guided targeted biopsies
CONCLUSIONS: Urologist seniority is not associated with CDR, urologist experience tends to improve cancer detection, and CDR does not differ between the anterior and posterior regions of the prostate.PMID:38245408 | DOI:10.1016/j.urolonc.2023.11.007 (Source: Urologic Oncology)
Source: Urologic Oncology - January 20, 2024 Category: Urology & Nephrology Authors: Fayek Taha St éphane Larre Benjamin Branchu ReSurg Source Type: research
Simplified cardiovascular index may be the best comorbidity index for clinical use in prediction of mortality for renal cancer patients
CONCLUSION: Increasing comorbidity, age, tumor size, and cM stage are predictors of ACM for suspected renal cancer patients. CVI appears to provide comparable information to various iterations of CCI (uCCI, aCCI) while being the simplest to use. Utilization of CVI may assist clinicians and patients when considering between interventional and noninterventional approaches for suspected renal cancer.PMID:38242826 | DOI:10.1016/j.urolonc.2024.01.004 (Source: Urologic Oncology)
Source: Urologic Oncology - January 19, 2024 Category: Urology & Nephrology Authors: Dennis Boynton Sabrina L Noyes Adharsh Murali Henry Peabody Andrew Krumm Karandeep Singh Brian R Lane Source Type: research
Longer time to radical cystectomy in patients treated with neoadjuvant chemotherapy is associated with worse oncological outcomes
CONCLUSIONS: A longer TTRC is associated with worse oncological outcomes in patients treated with NAC and RC.PMID:38238116 | DOI:10.1016/j.urolonc.2023.12.014 (Source: Urologic Oncology)
Source: Urologic Oncology - January 18, 2024 Category: Urology & Nephrology Authors: Siberyn T Nuijens Frits H M van Osch Lisa M C van Hoogstraten J Alfred Witjes Katja K H Aben Tom J N Hermans Source Type: research
Age related trends in the utilization of neoadjuvant chemotherapy for muscle invasive bladder cancer
CONCLUSION: Rates of NAC use prior to RC have increased among all age groups with the lowest utilization rate among the elderly. NAC use was associated with greater pathologic downstaging in all age groups. These data show a promising trend in the uptake of the gold standard for treatment of MIBC; however, the underlying etiology of differing rates of NAC utilization remains to be determined.PMID:38238117 | DOI:10.1016/j.urolonc.2024.01.006 (Source: Urologic Oncology)
Source: Urologic Oncology - January 18, 2024 Category: Urology & Nephrology Authors: Abigail Kohut-Jackson Jeffrey Orf Dominic Barresi Facundo Davaro Zachary Hamilton Source Type: research
The presence of intraductal carcinoma of prostate is a risk factor for poor pathologic response in men with high-risk prostate cancer receiving neoadjuvant therapy
CONCLUSION: IDC-P on biopsy pathology was found to be an independent risk factor to predict a poor pathology response of primary CaP to neoadjuvant therapies.PMID:38233262 | DOI:10.1016/j.urolonc.2023.11.018 (Source: Urologic Oncology)
Source: Urologic Oncology - January 17, 2024 Category: Urology & Nephrology Authors: Binyu Wang Yao Fu Mengxia Chen Shan Peng Giancarlo Marra Junlong Zhuang Shiwei Zhang Hongqian Guo Xuefeng Qiu Source Type: research
Telemedicine in urologic oncology care: Will telemedicine exacerbate disparities?
CONCLUSION: The lower rates of telemedicine use among Black patients could exacerbate pre-existing disparities in prostate, bladder, and kidney cancer outcomes.PMID:38220521 | DOI:10.1016/j.urolonc.2023.10.002 (Source: Urologic Oncology)
Source: Urologic Oncology - January 14, 2024 Category: Urology & Nephrology Authors: Zeynep G Gul Danielle R Sharbaugh Chad Ellimoottil Kimberly J Rak Jonathan G Yabes Benjamin J Davies Bruce L Jacobs Source Type: research
Precision medicine for urothelial carcinoma: An international perspective
Urol Oncol. 2024 Jan 12:S1078-1439(23)00360-5. doi: 10.1016/j.urolonc.2023.11.008. Online ahead of print.ABSTRACTThe treatment landscape of urothelial cancers has evolved in the last decade with the approval of chemotherapy, immune checkpoint inhibitors, targeted therapies, and antibody drug conjugates. Although improvements in response and survival have been achieved with these strategies, in some scenarios their benefit is still questionable. Current efforts to identify prognostic and predictive biomarkers are crucial for better patient selection and treatment outcomes. In this paper we will review the most promising bio...
Source: Urologic Oncology - January 13, 2024 Category: Urology & Nephrology Authors: Mariane S Fontes Daniel Vargas Pivato de Almeida Flavio C árcano Paulo Lages Rodrigo Dienstmann Source Type: research
Network meta-analysis of second line and beyond treatment options in metastatic clear cell renal cell carcinoma
CONCLUSION: Based on OS and PFS, the lenvtatinib + everolimus combination yielded superior, followed by cabozantinib and Lenvatinib monotherapies; all were limited by a worse SAE profile. Nivolumab and pazopanib had the lowest odds of SAEs.PMID:38216444 | DOI:10.1016/j.urolonc.2023.12.002 (Source: Urologic Oncology)
Source: Urologic Oncology - January 12, 2024 Category: Urology & Nephrology Authors: Mavis Obeng-Kusi Jordyn J Kreutzfeldt Ricardo J Estrada-Mendizabal Briana M Choi Ivo Abraham Alejandro Recio-Boiles Source Type: research
